Market Place
Sourcing Support
Citius Oncology Closes $9.0M Direct Offering & Private Placement
11 Sep 2025 //
PR NEWSWIRE
Citius Oncology Price $9.0M Direct Offering and Private Placement
09 Sep 2025 //
PR NEWSWIRE
Citius Oncology Use AI to Boost Performance Before LYMPHIR Launch
23 Aug 2025 //
PR NEWSWIRE
Citius Oncology Reports Q3 2025 Financial Results & Update
12 Aug 2025 //
PR NEWSWIRE
Rare Disease Clinical Progress Boosts Long-Term Revenue Potential
07 Aug 2025 //
PR NEWSWIRE
Citius Oncology Announces Closing of $9.0 Million Public Offering
17 Jul 2025 //
PR NEWSWIRE
Citius Oncology Prices $9.0 Million Public Offering
16 Jul 2025 //
PR NEWSWIRE
Citius Oncology Expands LYMPHIR Distribution with Cencora
15 Jul 2025 //
PR NEWSWIRE
Citius Oncology partners with Cardinal Health For Distribution
09 Jun 2025 //
PR NEWSWIRE
Citius Oncology Reports Q2 2025 Financials and Business Update
14 May 2025 //
PR NEWSWIRE
Citius Oncology Reports Q1 FY25 Results, Provides Update
14 Feb 2025 //
PR NEWSWIRE
Citius Pharma Announces Permanent J-Code for LYMPHIR by CMS
06 Feb 2025 //
PR NEWSWIRE
Citius Plans LYMPHIR Commercial Launch In First Half Of 2025
07 Jan 2025 //
PR NEWSWIRE
Citius Oncology Engages Jefferies To Explore Strategic Alternatives
06 Jan 2025 //
PR NEWSWIRE
Citius Oncology Reports 2024 Financial Results and Business Update
27 Dec 2024 //
PR NEWSWIRE
Citius Pharma Announces Promising Pembrolizumab Trial Results
11 Nov 2024 //
PR NEWSWIRE
Copyright © 2025 LePro PharmaCompass OPC Private Limited, All rights reserved.